SISRAM MED (01696) announced its interim results for the six months ended June 30, 2025, reporting revenue of $165 million, a decrease of 1.9% year-over-year. Profit attributable to owners of the parent company was $6.426 million, down 41.3% compared to the same period last year. Basic earnings per share stood at 1.37 US cents.

During the period, the group's revenue declined year-over-year, primarily due to challenging market conditions in North America, including high interest rates and weak consumer sentiment. Additionally, transportation restrictions in June caused by regional tensions led to slight delays in revenue recognition. Excluding the adverse factors in the North American market, SISRAM MED's international markets achieved 7.1% growth compared to the same period in 2024.

As of June 30, 2025, the order backlog remained robust, increasing by several million dollars compared to the same period in 2024. The gross profit margin decreased to 60.0% in the reporting period from 62.4% in the same period of 2024. This decline was mainly attributable to the strategic shift in product mix toward core professional-grade and precision high-end products, which resulted in higher material costs due to the adoption of cutting-edge technical specifications, while also being affected by the reduced proportion of North American revenue.